# Nutrition/Interventional - SWITZERLAND

#### **Competent authority**

Contact Details

#### **Contact Name 1**

Swissmedic - Schweizerisches Heilmittelinstitut / Swiss Agency for Therapeutics products Clinical Trials Division

#### **Phone**

+41 31 322 02 11

#### Fax

+41 31 322 02 12

#### **Email General**

ct.medicinalproducts@swissmedic.ch

#### **Address**

Hallerstrasse 7

#### ZIP/City

3000 Bern 9

#### **Country**

Switzerland (CH)

#### Web address

http://www.swissmedic.ch/

Trial Authorisation / Registration / Notification

#### Regulatory and ethics bodies involved in approval process

Institutional Ethics Committee Regional Ethics Committee National Ethics Committee

Regulatory and ethics bodies involved in approval process for trials including patients

\_

Regulatory and ethics bodies involved in approval process for trials including including healthy participants

\_

Regulatory and ethics bodies involved in approval process for trials including vulnerable population

\_

CA - Registration/ notification without approval required for

\_

**CA - Registration requirements for clinical trials** 

Registration mandatory

Registration requirements for clinical trials including patients

\_

Registration requirements for clinical trials including healthy participants Registration requirements for clinical trials including vulnerable population **CA - Submission required to** Institutional CA Studies including patients - submission required to Studies including healthy participants - submission required to Studies including vulnerable population - submission required to Language of Submission Language(s) of application English Language(s) of application for trials including patients Language(s) of application for trials including healthy participants Language(s) of application for trials including vulnerable population Preferred language of application **English accepted** Yes Documents mandatory to be in official national language Documents mandatory to be in local language of study site Documents mandatory to be in language of the study participant Safety Reporting Sponsor must declare reportable events to **Ethics committee Contact Details Contact Name 1** 

> Swissethics- Schweizerische Ethikkommissionen für die Forschung am Menschen / Swiss Association of Ethics Committees for research on humans

#### **Contact Name 2**

Geschäftsstelle Swissethics/AGEK (Arbeitsgemeinschaft der Schweizer Ethikkommissionen)

## Phone 041 440 26 67 **Address** Haus der Akademien - Laupenstrasse 7 ZIP/City 3008 Bern Country Switzerland (CH) E-Mail info@swissethics.ch Web address http://www.swissethics.ch/ **Additional Information** The Swiss Ethics Committees on research involving humans have formed a joint working group (swissethics). Swissethics is organised as an association, its members are all the recognised regional/cantonal ethics committees of Switzerland. List of all Ethics Committees in Switzerland: http://www.swissethics.ch/eks.html Ethical Review - General Submission for Ethical review mandatory for Submission of study mandatory for trials including patients Yes Submission of study mandatory for trials including healthy participants Yes Submission to CA and EC to be performed in the following order National declaration on Ethical requirements exists Single-Centre Studies -Ethical approval (favourable opinion) to be obtained from **Ethical Review** Institutional EC Ethical approval (favourable opinion) for trials including patients to be obtained from Ethical approval (favourable opinion) for trials including healthy participants to be obtained from Ethical approval (favourable opinion) for trials including vulnerable population to be obtained from Multi-Centre Studies -Ethical approval (favourable opinion) required from **Ethical Review**

	Ethical approval in trials including patients obtained from
	<del>-</del>
	Ethical approval in trials including healthy participants obtained from
	Ethical approval in trials including vulnerable population obtained from
	<del>-</del>
Submission of Application	Entitled to study submission
	<del>-</del>
	Entitled to submission of trials including patients
	Principal Investigator Investigator Physician PhD
	Entitled to submission of trials including healthy participants
	Principal Investigator Investigator
	Physician PhD
	Responsible for submission of trials including vulnerable population
	Provoquisitos for submission / approval
	Prerequisites for submission / approval
Language of Submission	Language(s) of application
Language of Submission	Language(s) of application
Language of Submission	English
Language of Submission	
Language of Submission	English  Language(s) of application for trials including patients  -
Language of Submission	English
Language of Submission	English  Language(s) of application for trials including patients  Language(s) of application for trials including healthy participants
Language of Submission	English  Language(s) of application for trials including patients  -
Language of Submission	English  Language(s) of application for trials including patients  Language(s) of application for trials including healthy participants  Language(s) of application for trials including vulnerable population  —
Language of Submission	English  Language(s) of application for trials including patients  Language(s) of application for trials including healthy participants  Language(s) of application for trials including vulnerable population
Language of Submission	English  Language(s) of application for trials including patients  Language(s) of application for trials including healthy participants  Language(s) of application for trials including vulnerable population  Preferred language of application  —
Language of Submission	English  Language(s) of application for trials including patients  Language(s) of application for trials including healthy participants  Language(s) of application for trials including vulnerable population  —
Language of Submission	English  Language(s) of application for trials including patients  Language(s) of application for trials including healthy participants  Language(s) of application for trials including vulnerable population  Preferred language of application  English accepted  Yes
Language of Submission	English  Language(s) of application for trials including patients  Language(s) of application for trials including healthy participants  Language(s) of application for trials including vulnerable population  Preferred language of application  English accepted
Language of Submission	English  Language(s) of application for trials including patients  Language(s) of application for trials including healthy participants  Language(s) of application for trials including vulnerable population  Preferred language of application  English accepted  Yes
Language of Submission	English  Language(s) of application for trials including patients  Language(s) of application for trials including healthy participants  Language(s) of application for trials including vulnerable population  Preferred language of application  English accepted  Yes  Documents mandatory to be in official national language  —
Language of Submission	English  Language(s) of application for trials including patients  Language(s) of application for trials including healthy participants  Language(s) of application for trials including vulnerable population  Preferred language of application  English accepted  Yes  Documents mandatory to be in official national language  —
Language of Submission	English  Language(s) of application for trials including patients  Language(s) of application for trials including healthy participants  Language(s) of application for trials including vulnerable population  Preferred language of application  English accepted  Yes  Documents mandatory to be in official national language  Documents mandatory to be in local language of study site
Timelines Ethical Review	English  Language(s) of application for trials including patients  Language(s) of application for trials including healthy participants  Language(s) of application for trials including vulnerable population  Preferred language of application  English accepted  Yes  Documents mandatory to be in official national language  Documents mandatory to be in local language of study site

Time in weeks from submission to positive approval (maximum)
8
Time in weeks from submission to positive approval (average)
5
Safety Reporting
Investigator shall report SAE to
Institution
Sponsor
Investigator shall report SAE in trials with patients to
—
Investigator shall report SAE in trials with healthy participants to
—
Investigator shall report SAE in trials with volunteers to

### Study specific Requirements

Study specific Requirements		
Sponsor	Sponsorship mandatory in trials with patients	
	Yes	
	Sponsorship mandatory in trials with healthy participants	
	Yes	
	Co-sponsorship allowed in trials with patients	
	Yes	
	Co-sponsorship allowed in trials with healthy participants	
	Yes	
Study Participants -	Standard IC form (ICF) available	
Informed Consent (IC)	Not specified	
	Accepted format of Informed Consent (IC) form	
	-	
	Accepted format of IC form for studies including patients	
	Written consent	
	Accepted format of IC form for studies including healthy participants	
	Written consent	
	Accepted format of IC form for studies including vulnerable population	
	_	
Study Participants - Vulnerable Population	Considered as vulnerable population	
	Children People with psychiatric disorder People with dementia Prisoners	
	Regulations concerning the inclusion or exclusion available	
	Yes	

	Applicable ethical regulations
Study Participants - Compensation & Reimbursement	Reimbursement for study participants
	Reimbursement for patients
	Mandatory
	Reimbursement for healthy participants
	Optional
	Reimbursement for vulnerable population
	-
	Compensation is limited to/provided for
	_
	Compensation for patients is limited to/provided for
	Compensation for healthy participants is limited to/provided for
	Compensation for vulnerable population is limited to/provided for
	_
Insurance	Liability insurance or alternative arrangements for damages mandatory for
	_
	Obligation to contract a liability insurance for trials including patients for
	Patients/Volunteers
	Obligation to contract a liability insurance for trials including healthy participants for
	Patients/Volunteers
	Obligation to contract a liability insurance for trials including vulnerable population for
	-
	Insurance fee in € value indicated as —
	Insurance fee in € value indicated as
	_
Quality Assurance/ Quality Control (QA/QC)	Regularly performed methods
	Regularly performed methods in trials including patients
	Audits
	Monitoring Standard Operating Procedures (SOP) Case Report Form (CRF)

## Regularly performed methods in trials including healthy participants **Audits** Monitoring Standard Operating Procedures (SOP) Case Report Form (CRF) Regularly performed methods in trials including vulnerable population Regularly performed audits Regularly performed audits in trials including patients Regularly performed audits in trials including healthy participants Regularly performed audits in trials including vulnerable population **Additional Information** internal audits are regularly performed in interventional trials in patients and in healthy participants National legislation General Information: **Applied regulatory conventions** Applicable Legislation & Conventions Applied regulatory conventions in studies including patients Declaration of Helsinki Other ethical principles for medical research (other than Declaration of Helsinki) Applied regulatory conventions in studies including healthy participants Declaration of Helsinki **ICH-GCP Guidelines** Other guidelines for good clinical practice (other than ICH-GCP) Applied regulatory conventions in studies including vulnerable population **Applicable national laws** Applicable national laws for patients Applicable national laws for healthy participants Applicable national laws for vulnerable population National regulations for volunteers exist for

Nutrition	Nutrition considered as drug
	No
Blood & Tissue Samples	Tissue samples permitted in trials including patients
	Yes
	Tissue samples permitted in trials including healthy participants
	Yes